Madrid

• LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and … Recruiting
  2023-508995-12-01 4 2025-12-24 Recurrent or metastatic non-small cell lung cancer (NSCLC)
• A study to compare Efficacy, Safety and How the Body Absorbs, Distributes, and Eliminates of Subcutaneous CT-P44 and Darzalex Faspro in Comb … Recruiting
  2024-518588-36-00 5 2025-12-24 Refractory or Relapsed Multiple Myeloma
• A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting
  2023-507525-42-00 5 2025-12-23 Endometrial cancer
• Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano … Recruiting
  2022-503140-41-00 5 2025-12-19 Melanoma
• A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear … Recruiting
  2023-505661-89-00 4 2025-12-19 Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
• A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be … Recruiting
  2024-510778-26-00 4 2025-12-19 Metastatic Non-Small-Cell Lung Cancer
• CLEOPATTRA: A research study to look at the effects of treatment with a medicine called coramitug (NNC6019-0001) in people with heart failur … Recruiting
  2024-518899-31-00 5 2025-12-19 Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
• A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors Recruiting
  2025-521672-60-00 7 2025-12-19 Metastatic or locally advanced SST2-positive neuroendocrine neoplasms
• RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab Recruiting
  2024-514327-42-00 4 2025-12-18 Advanced neuroendocrine carcinomas (NECs) of the digestive system or u
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• Study of GS-5319 in Adults With Solid Tumors Recruiting
  2025-522397-36-00 1 2025-12-18 Advanced solid tumors
• A clinical study to assess the efficacy of adjuvant immunotherapy with cemiplimab in patients with surgically removed non-small cell lung ca … Recruiting
  2024-519901-36-00 5 2025-12-17 Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
• Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testi … Recruiting
  2025-521780-12-00 11 2025-12-16 Non-ischemic cardiomyopathy
• A study to test how well an oral medication called rilzabrutinib works and how safe it is for adults with immune thrombocytopenia (ITP) who … Recruiting
  2025-522070-36-00 5 2025-12-15 immune thrombocytopenia (ITP)
• Personalized Treatment for Endometriosis: A Study on the Safety and Kinetics of Dienogest in Women with Different Gene Variants Recruiting
  2025-521026-15-00 3 2025-12-11 Healthy volunteers
• A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment Recruiting
  2024-517923-38-00 3 2025-12-10 Newly diagnosed and/or previously treated IDH1-mutated malignancies
• SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION Recruiting
  2025-520794-39-00 5 2025-12-10 Arterial Hypertension
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• A multicenter, open-label, Phase 2 study of TYRA-300 in non-muscle invasive bladder cancer Recruiting
  2025-521277-14-00 4 2025-12-09 Non-muscle invasive bladder cancer (NMIBC)
• Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting
  2025-521293-34-00 4 2025-12-09 Moderate-to-severe hidradenitis suppurativa
• A study comparing nadofaragene firadenovec with standard of care in adults with an increased risk that non-muscle invasive bladder cancer ma … Recruiting
  2024-512029-10-00 5 2025-12-05 Intermediate risk, non-muscle invasive bladder cancer
• A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or … Recruiting
  2025-521034-28-00 4 2025-12-05 Moderate to Severe Rheumatoid Arthritis (RA)
• Phase 2a Study of VX-407 in Subjects with ADPKD Who Have a Subset of PKD1 Gene Variants Recruiting
  2024-517393-13-00 4 2025-12-02 Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus … Recruiting
  2024-520356-24-00 4 2025-12-01 Refractory Metastatic Colorectal Cancer with Liver Dominant Disease

Showing 361–384 of 3,550 trials